Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer

  • Fernandes Alves, Joao Miguel
  • Estevez Gomez, Nuria
  • Valecha , Monica Vishnu
  • Prado López, Sonia
  • Tomás López, Laura
  • Alvariño Sanjurjo, Pilar
  • Silva Piñeiro, Roberto
  • Muinelo Romay, Laura
  • Mondelo Macía, Patricia
  • Salgado, Mercedes
  • Iglesias Gómez, Agueda
  • Codesido Prada, Laura
  • Cubiella Fernández, Joaquín
  • Posada González, David
Financiado para publicación en acceso aberto: Universidade de Vigo/CISUG, The genomic profiling of circulating tumor cells (CTCs) in the bloodstream should provide clinically relevant information on therapeutic efficacy and help predict cancer survival. Here, we contrasted the genomic profiles of CTC pools recovered from metastatic colorectal cancer (mCRC) patients using different enrichment strategies (CellSearch, Parsortix, and FACS). Mutations inferred in the CTC pools differed depending on the enrichment strategy and, in all cases, represented a subset of the mutations detected in the matched primary tumor samples. However, the CTC pools from Parsortix, and in part, CellSearch, showed diversity estimates, mutational signatures, and drug-suitability scores remarkably close to those found in matching primary tumor samples. In addition, FACS CTC pools were enriched in apparent sequencing artifacts, leading to much higher genomic diversity estimates. Our results highlight the utility of CTCs to assess the genomic heterogeneity of individual tumors and help clinicians prioritize drugs in mCRC., Agencia Estatal de Investigación | Ref. PID2019-106247GB-I00, Xunta de Galicia | Ref. ED481A-2018/303, Instituto de Salud Carlos III | Ref. PI17/00837, Instituto de Salud Carlos III | Ref. PI21/01771, Axencia Galega de Innovación | Ref. N607B-2020/02, Axencia Galega de Innovación | Ref. IN853B 2018/03
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: a community‐based cohort study

  • Pin Vieito, Noel
  • García Nimo, Laura
  • Bujanda, Luis
  • Román Alonso, Begoña
  • Gutiérrez Stampa, María Ángeles
  • Aguilar Gama, Vanessa
  • Portillo, Isabel
  • Cubiella Fernández, Joaquín
Background Optimizing colonoscopy resources is challenging, and information regarding performing diagnostic quantitative faecal immunochemical test (FIT) in daily clinical practice in primary health care is still limited. This study aimed to assess the sensitivity, specificity, positive predictive value and negative predictive value of varying FIT positivity thresholds on colorectal cancer (CRC) detection in primary health care. Methods A retrospective cohort study of 38,675 asymptomatic and symptomatic patients with a FIT (OC-Sensor™) performed between 2012 and 2016 in a primary health-care setting, using a clinical laboratory database of two Spanish areas linked with the National Health System's Hospital Discharge Records Database. The primary outcome was 2-year CRC incidence. Results The mean age of the participants was 63.2 years; 17,792 (46.0%) were male. CRC prevalence was 1.7% (650/38,675). The percentage of patients with a FIT result above the threshold was 20.7% and 14.6% for 10 μg Hb/g faeces and 20 μg Hb/g faeces thresholds, respectively. Sensitivity was 90.5% (95% confidence interval 88.0%–92.5%) at a 10 μg Hb/g faeces threshold, and this decreased by 3.1% when a 20 μg Hb/g faeces threshold was used. The negative predictive value for CRC was at least 99.2% in any subgroup analysed. At a 20 μg Hb/g faeces threshold, less than one additional CRC would be missed per 1000 patients investigated, while approximately 1.3 times more colonoscopy examinations were needed to identify an incidence of CRC using the lowest threshold for any situation analysed. Conclusions In primary health care, a quantitative FIT threshold should be tailored to colonoscopy capacity and CRC prevalence in specific populations., Instituto de Salud Carlos III, España | Ref. PI17/00837
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Predictive value of carcinoembryonic antigen in symptomatic patients without colorectal cancer: A post-hoc analysis within the COLONPREDICT cohort

  • Pin Vieito, Noel
  • Iglesias, María José
  • Remedios, David
  • Álvarez Sánchez, Patricia
  • Fernández Bañares, Fernando
  • Boadas, Jaume
  • Martínez Bauer, Eva
  • Campo, Rafael
  • Bujanda, Luis
  • Ferrández, Ángel
  • Piñol, Virginia
  • Rodríguez Alcalde, Daniel
  • Menéndez Rodríguez, Martín
  • García Morales, Natalia
  • Pérez Mosquera, Cristina
  • Cubiella Fernández, Joaquín
We aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 ± 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3–3.1), CRC (HR 4.4, 95% CI 1.1–17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0–2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3–5.8), rectal bleeding (OR 0.3, 95% CI 0.1–0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7–7.1). However, CEA was increased only in 31.8% (95% CI, 16.4–52.7%) and 50% (95% CI, 25.4–74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC., Instituto de Salud Carlos III, España | Ref. PI17/00837
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

  • Pin-Vieito, N.
  • Iglesias, M. J.
  • Remedios, D.
  • Rodríguez-Alonso, L.
  • Rodriguez-Moranta, F.
  • Álvarez-Sánchez, V.
  • Fernández-Bañares, F.
  • Boadas, J.
  • Martínez-Bauer, E.
  • Campo, R.
  • Bujanda, L.
  • Ferrandez, Á.
  • Piñol, V.
  • Rodríguez-Alcalde, D.
  • Guardiola, J.
  • Cubiella, J.
  • González-López, N.
  • Quintero, E.
  • Bañales, J.
  • Bujanda, L.
  • Perugorria, M. J.
  • Cleries, R.
  • Ribes, J.
  • Sanz, X.
  • López-Vicente, J.
  • Rodriguez-Alcalde, D.
  • Piñol, V.
  • Torrealba, L.
  • Blanco, I.
  • Cubiella, J.
  • Díaz-Ondina, M.
  • Salve, M.
  • Fernández-Seara, J.
  • Iglesias, M. J.
  • Macía, P.
  • Remedios, D.
  • Sánchez, E.
  • Vega, P.
  • Campo, R.
  • Martínez-Bauer, E.
  • Pujol, M.
  • Sánchez, V. Á.
  • Mera, J.
  • Turnes, J.
  • Clofent, J.
  • Garayoa, A.
  • Fernández-Bañares, F.
  • Gonzalo, V.
  • Pujals, M.
  • Boadas, J.
  • Galter, S.
  • Garcia-Lanuza, E.
  • Gimeno, R.
  • Alsius, A.
  • Ferrández, Á.
  • Sánchez, M. S.
BACKGROUND: Faecal immunochemical test (FIT) has been recommended to assess symptomatic patients for colorectal cancer (CRC) detection. Nevertheless, some conditions could theoretically favour blood originating in proximal areas of the gastrointestinal tract passing through the colon unmetabolized. A positive FIT result could be related to other gastrointestinal cancers (GIC). AIM: To assess the risk of GIC detection and related death in FIT-positive symptomatic patients (threshold 10 µg Hb/g faeces) without CRC. METHODS: Post hoc cohort analysis performed within two prospective diagnostic test studies evaluating the diagnostic accuracy of different FIT analytical systems for CRC and significant colonic lesion detection. Ambulatory patients with gastrointestinal symptoms referred consecutively for colonoscopy from primary and secondary healthcare, underwent a quantitative FIT before undergoing a complete colonoscopy. Patients without CRC were divided into two groups (positive and negative FIT) using the threshold of 10 µg Hb/g of faeces and data from follow-up were retrieved from electronic medical records of the public hospitals involved in the research. We determined the cumulative risk of GIC, CRC and upper GIC. Hazard rate (HR) was calculated adjusted by age, sex and presence of significant colonic lesion. RESULTS: We included 2709 patients without CRC and a complete baseline colonoscopy, 730 (26.9%) with FIT = 10 µgr Hb/gr. During a mean time of 45.5 ± 20.0 mo, a GIC was detected in 57 (2.1%) patients: An upper GIC in 35 (1.3%) and a CRC in 14 (0.5%). Thirty-six patients (1.3%) died due to GIC: 22 (0.8%) due to an upper GIC and 9 (0.3%) due to CRC. FIT-positive subjects showed a higher CRC risk (HR 3.8, 95%CI: 1.2-11.9) with no differences in GIC (HR 1.5, 95%CI: 0.8-2.7) or upper GIC risk (HR 1.0, 95%CI: 0.5-2.2). Patients with a positive FIT had only an increased risk of CRC-related death (HR 10.8, 95%CI: 2.1-57.1) and GIC-related death (HR 2.2, 95%CI: 1.1-4.3), with no differences in upper GIC-related death (HR 1.4, 95%CI: 0.6-3.3). An upper GIC was detected in 22 (0.8%) patients during the first year. Two variables were independently associated: anaemia (OR 5.6, 95%CI: 2.2-13.9) and age = 70 years (OR 2.7, 95%CI: 1.1-7.0). CONCLUSION: Symptomatic patients without CRC have a moderate risk increase in upper GIC, regardless of the FIT result. Patients with a positive FIT have an increased risk of post-colonoscopy CRC.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort

  • Pin-Vieito, N.
  • Iglesias, M.J.
  • Remedios, D.
  • Alvarez-Sanchez, V.
  • Fernandez-Banares, F.
  • Boadas, J.
  • Martinez-Bauer, E.
  • Campo, R.
  • Bujanda, L.
  • Ferrandez, A.
  • Pinol, V.
  • Rodriguez-Alcalde, D.
  • Menendez-Rodriguez, M.
  • Garcia-Morales, N.
  • Perez-Mosquera, C.
  • Cubiella, J.
We aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 +/- 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3-3.1), CRC (HR 4.4, 95% CI 1.1-17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0-2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3-5.8), rectal bleeding (OR 0.3, 95% CI 0.1-0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7-7.1). However, CEA was increased only in 31.8% (95% CI, 16.4-52.7%) and 50% (95% CI, 25.4-74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC.